Ironwood Pharmaceuticals, Inc. (IRWD)

Ironwood Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	308.52	351.41	442.74	410.6	413.75	389.52
Revenue Growth (YoY)	-22.98%	-20.63%	7.83%	-0.76%	6.22%	-9.08%
Cost of Revenue	2.15	7.55	6.15	4.94	70.41	91.2
Gross Profit	306.37	343.86	436.59	405.66	343.35	298.33
Selling, General & Admin	110.76	144.27	142.11	115.99	111.13	140
Research & Development	103.87	103.87	98.64	39.33	-	-
Operating Expenses	214.63	248.14	240.75	155.32	111.13	140
Operating Income	91.74	95.72	195.84	250.34	232.22	158.32
Interest Expense	-34.76	-33.29	-21.38	-7.6	-31.15	-29.48
Interest & Investment Income	3.62	4.47	18.97	9.5	0.73	1.5
Other Non Operating Income (Expenses)	0.72	0.89	-0.23	0.18	-1.18	-6.11
EBT Excluding Unusual Items	61.31	67.79	193.2	252.42	200.61	124.24
Merger & Restructuring Charges	-18.4	-2.59	-45.82	-	0.04	-15.38
Pretax Income	42.91	65.2	-948.07	252.42	200.66	108.86
Income Tax Expense	50.8	64.32	83.49	77.36	-327.79	2.69
Earnings From Continuing Operations	-7.89	0.88	-1,032	175.07	528.45	106.18
Net Income to Company	-7.89	0.88	-1,032	175.07	528.45	106.18
Minority Interest in Earnings	-	-	29.32	-	-	-
Net Income	-7.89	0.88	-1,002	175.07	528.45	106.18
Net Income to Common	-7.89	0.88	-1,002	175.07	528.45	106.18
Net Income Growth	-	-	-	-66.87%	397.71%	393.73%
Shares Outstanding (Basic)	161	159	155	154	162	159
Shares Outstanding (Diluted)	161	160	155	186	164	161
Shares Change (YoY)	2.18%	2.99%	-16.57%	13.32%	2.34%	2.97%
EPS (Basic)	-0.05	0.01	-6.45	1.13	3.26	0.67
EPS (Diluted)	-0.05	0.01	-6.45	0.96	3.21	0.66
EPS Growth	-	-	-	-69.98%	386.36%	378.84%
Free Cash Flow	29.94	103.41	183.15	273.63	261.63	166.99
Free Cash Flow Per Share	0.19	0.65	1.18	1.47	1.59	1.04
Gross Margin	99.30%	97.85%	98.61%	98.80%	82.98%	76.59%
Operating Margin	29.73%	27.24%	44.23%	60.97%	56.12%	40.64%
Profit Margin	-2.56%	0.25%	-226.37%	42.64%	127.72%	27.26%
Free Cash Flow Margin	9.70%	29.43%	41.37%	66.64%	63.23%	42.87%
EBITDA	93.68	97.73	197.41	251.76	233.74	160.69
EBITDA Margin	30.36%	27.81%	44.59%	61.31%	56.49%	41.25%
D&A For EBITDA	1.94	2.01	1.58	1.42	1.52	2.36
EBIT	91.74	95.72	195.84	250.34	232.22	158.32
EBIT Margin	29.73%	27.24%	44.23%	60.97%	56.12%	40.64%
Effective Tax Rate	118.37%	98.65%	-	30.65%	-	2.47%
Revenue as Reported	308.52	351.41	442.74	410.6	413.75	389.52

Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q